|
Biogen Acquires Remedy Pharmaceuticals’ Late-Stage Drug CIRARA™
New York, NY – May 18, 2017 – Remedy Pharmaceuticals, a privately-held pharmaceutical company focused on bringing life-saving treatments to people affected by central nervous system diseases and injuries, today announced that Biogen (NASDAQ: BIIB) completed an asset purchase of its Phase 3 candidate, CIRARA. Biogen made an upfront payment of $120 million to Remedy and may also pay additional milestone payments and royalties. The target indication for CIRARA is large hemispheric infarction, a severe form of ischemic stroke where brain swelling often leads to disproportionately large share of stroke-related morbidity and mortality. The U.S. Food and Drug Administration (FDA) recently granted CIRARA Orphan drug designation for severe cerebral edema in patients with acute ischemic stroke. The FDA has also granted CIRARA Fast Track designation. “We’ve spent over a decade on this mission to bring CIRARA to this desperately-in-need patient population,” notes David Geliebter, Executive Chairman, Remedy Pharmaceuticals. "Biogen’s expertise in CNS brings us closer to helping people afflicted with central nervous system related edema to not only survive, but live life to the fullest.” “While one chapter closes for us, another exciting one begins for Remedy,” says Sven Jacobson, CEO of Remedy Pharmaceuticals, “As we seek out other innovative life science opportunities that play to our core strengths and values.” About Biogen Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Founded in 1978, Biogen is a pioneer in biotechnology, and today the company has the leading portfolio of medicines to treat multiple sclerosis; has introduced the first and only approved treatment for spinal muscular atrophy; and is at the forefront of neurology research for conditions including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. Biogen also manufactures and commercializes biosimilars of advanced biologics. About Remedy Pharmaceuticals Founded in 2005, Remedy Pharmaceuticals, Inc. is a privately-held pharmaceutical company focused on improve the lives of patients with CNS-related illnesses and injuries through cutting-edge science and unconventional thinking. Remedy is based in New York City. Contact: Remedy Pharmaceuticals Sven Jacobson 212-586-2226 x 225 sven@remedypharmaceuticals.com
0 Comments
BIOGEN ACQUIRES REMEDY PHARMACEUTICALS’ CIRARA FOR LARGE HEMISPHERIC STROKE
CAMBRIDGE, Mass. – May 15, 2017 – Biogen (NASDAQ: BIIB) announced today that it has completed an asset purchase of Remedy Pharmaceuticals’ Phase 3 candidate, CIRARA™ (intravenous glyburide). The target indication for CIRARA is large hemispheric infarction (LHI), a severe form of ischemic stroke where brain swelling (cerebral edema) often leads to a disproportionately large share of stroke-related morbidity and mortality. The U.S. Food and Drug Administration (FDA) recently granted CIRARA Orphan Drug Designation for severe cerebral edema in patients with acute ischemic stroke. The FDA has also granted CIRARA Fast Track designation. Each year approximately 1.7 million ischemic strokes occur across the U.S., Europe and Japan, and approximately 15 percent of these are LHI strokes. In pre-clinical studies, CIRARA has been shown to block SUR1-TRPM4 channels that mediate stroke related brain swelling. Clinical proof-of-concept studies have demonstrated the potential of CIRARA to reduce brain swelling, disability and the risk of death in patients with LHI. “We see an opportunity to make a major difference in patient care by advancing new treatments for stroke. CIRARA represents a potential breakthrough stroke treatment that accelerates our efforts to build a portfolio of new therapies for neurologic diseases,” said Michael Ehlers, M.D., Ph.D., Executive Vice President, Research and Development at Biogen. “We believe the data supporting the potential of CIRARA are compelling and that CIRARA can be a first-in-class therapy that gives physicians the ability to meaningfully improve patient outcomes in an area where effective treatments have been few and far between.” This transaction complements Biogen’s broader efforts to build a portfolio of best-in-class treatments for acute ischemic stroke and further strengthen its leadership in neuroscience. Biogen currently is conducting a Phase 2b study to determine whether its monoclonal antibody natalizumab, as a potential neuroprotective, can help patients with acute ischemic stroke improve functional outcomes and cognition. Biogen plans to continue the development and commercialization of CIRARA. Under the terms of the agreement, Remedy will share in the cost of development for the target indication for CIRARA in LHI stroke. Biogen will make an upfront payment of $120 million to Remedy and may also pay additional milestone payments and royalties. About Remedy Pharmaceuticals Remedy Pharmaceuticals, Inc. is a privately-held, clinical stage pharmaceutical company focused on developing and bringing lifesaving treatments to people affected by acute central nervous system (CNS) disease and injuries. About Biogen Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Founded in 1978, Biogen is a pioneer in biotechnology, and today the company has the leading portfolio of medicines to treat multiple sclerosis; has introduced the first and only approved treatment for spinal muscular atrophy; and is at the forefront of neurology research for conditions including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. Biogen also manufactures and commercializes biosimilars of advanced biologics. For more information, please visit www.biogen.com. Follow us on social media – Twitter, LinkedIn, Facebook, YouTube. Biogen Safe Harbor This press release contains forward-looking statements, made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements relating to the potential benefits and results that may be achieved through the license agreement with Remedy Pharmaceuticals, risks and uncertainties associated with drug development and commercialization, the potential benefits, safety and efficacy of investigational drugs including CIRARA and natalizumab and the anticipated completion and timing of the transaction. These forward-looking statements may be accompanied by words such as “anticipate,” “believe,” “could,” “estimate,” “except,” “forecast,” “intend,” “may,” “plan,” “potential,” “possible,” “will” and other words and terms of similar meaning. You should not place undue reliance on these statements or the scientific data presented. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including, without limitation: risks that the transaction will be completed in a timely manner or at all; uncertainty as to whether the anticipated benefits of the transaction can be achieved; risks of unexpected costs or delays; uncertainty of success in the development and potential commercialization of natalizumab and/or CIRARA, which may be impacted by, among other things, unexpected concerns that may arise from additional data or analysis, the occurrence of adverse safety events, failure to obtain regulatory approvals in certain jurisdictions, failure to protect and enforce our data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; product liability claims; and third party collaboration risks. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. Investors should consider this cautionary statement, as well as the risk factors identified in Biogen’s most recent annual or quarterly report and in other reports Biogen has filed with the U.S. Securities and Exchange Commission. These statements are based on our current beliefs and expectations and speak only as of the date of this press release. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise. Remedy Pharmaceuticals’ CIRARA Granted Orphan Drug Designation For Treatment of Severe Cerebral Edema Caused By Acute Ischemic Stroke
NEW YORK, New York, January 17, 2017 — Remedy Pharmaceuticals, a privately-held pharmaceutical company focused on bringing life-saving hospital-based treatments to people affected by central nervous system related edema, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its investigational drug, CIRARA, for treatment of severe cerebral edema in patients with acute ischemic stroke. “The Orphan Drug Designation, in addition to our FDA Fast Track status, is an important achievement as we advance our development plans for CIRARA to combat severe cerebral edema in large hemispheric infarction,” notes Sven Jacobson, CEO of Remedy Pharmaceuticals. “CIRARA could significantly enhance currently available treatment options for this desperately at-need patient population.” ABOUT ORPHAN DRUG DESIGNATION The Orphan Drug Designation Program is administered by the FDA's Office of Orphan Products Development, which grants orphan status to drugs which are intended to treat rare diseases that affect fewer than 200,000 people in the U.S., or diseases that affect more than 200,000 people in the U.S. in circumstances where there is not expectation of recovering the costs of developing and marketing a therapeutic drug. ABOUT CIRARA CIRARA is a patented, high affinity inhibitor of Sur1-Trpm4 channels, which are upregulated following ischemia and trauma. Opening of these channels can lead to severe edema, midline shift, increased intracranial pressure and brain herniation, culminating in permanent disability or death. Sur1-Trpm4 channels were discovered by University of Maryland neurosurgeon Dr. J. Marc Simard, scientific founder and board member of Remedy Pharmaceuticals. CIRARA is an investigational drug and is not approved by FDA. ABOUT REMEDY PHARMACEUTICALS Remedy Pharmaceuticals, Inc. is a privately-held, clinical stage pharmaceutical company focused on developing and bringing lifesaving treatments to people affected by acute central nervous system (CNS) edema. Contact: Remedy Pharmaceuticals Sven Jacobson 212-586-2226 x 225 sven@remedypharmaceuticals.com PRESS RELEASE
David Epstein Joins as Special Advisor to Remedy Pharmaceuticals Former Head of Novartis’ Pharmaceuticals Division to help guide future of company focused on groundbreaking therapy for CNS-related edema NEW YORK, New York, November 30, 2016 — Remedy Pharmaceuticals, a privately-held phase 3-ready pharmaceutical company focused on bringing a life-saving hospital-based treatment to people affected by central nervous system (CNS) related edema, today announced that David Epstein has joined as special advisor to the Company’s board of directors. Until earlier this year, Mr. Epstein spent two-and-a-half decades at Swiss-based Novartis, most recently as Division Head and CEO of the Pharmaceuticals business. Previously, Mr. Epstein started and led Novartis' Oncology and Molecular Diagnostics units. Under his leadership the Oncology business grew to number two in the world. He has more than 20 years of extensive drug development, deal making, commercialization and people leadership experience on a global scale. Over the course of his career he lead the development and commercialization of over 30 new molecular entities including major breakthroughs such as Glivec, Tasigna, Gilenya, Cosentyx and Entresto. Early in his career, Mr. Epstein was an Associate in the Strategy Practice of the consulting firm Booz, Allen and Hamilton. He was recently named by Fierce Biotech to be among "The 25 most influential in biopharma." "We are honored to be working with David,” said David Geliebter, Executive Chairman of Remedy Pharmaceuticals. “His unparalleled experience in drug development and commercialization will be indispensable as we continue to advance our product pipeline and explore prospective strategic alliances.” "I am excited about the science and the progress made to date," said David Epstein. “My goal is to help Remedy’s executive team accelerate their program so that as many patients as possible can benefit from this life-saving medicine." ABOUT CIRARA CIRARA is a patented, high affinity inhibitor of Sur1-Trpm4 channels, which are upregulated following ischemia and trauma. Opening of these channels can lead to edema, midline shift, increased intracranial pressure and brain herniation, culminating in permanent disability or death. Sur1-Trpm4 channels were discovered by University of Maryland neurosurgeon Dr. J. Marc Simard, scientific founder and board member of Remedy Pharmaceuticals. CIRARA is an investigational drug and is not approved by FDA. ABOUT REMEDY PHARMACEUTICALS Remedy Pharmaceuticals, Inc. is a privately-held, clinical stage pharmaceutical company focused on developing and bringing lifesaving treatment to people affected by acute central nervous system (CNS) edema. Contact: Remedy Pharmaceuticals Sven Jacobson 212-586-2226 x 225 sven@remedypharmaceuticals.com PRESS RELEASE
Remedy Pharmaceuticals’ Edema and Neuro-inflammation Advisory Board Provides Guidance on Opportunities in CNS Conditions NEW YORK, New York, August 18, 2016 — Remedy Pharmaceuticals, a privately-held phase 3-ready pharmaceutical company focused on bringing life-saving hospital-based treatment to people affected by central nervous system related edema, today announced the successful conclusion of a two-day scientific advisory board meeting in which a distinguished panel of experts provided recommendations on promising indications for the Company to consider pursuing in addition to its current programs. “This meeting underscores our commitment to continuing the development of innovative therapies for severe conditions where edema is a significant driver of clinical outcomes," says Sven Jacobson, CEO of Remedy Pharmaceuticals. Scientific advisors in attendance included (alphabetically) Daniel Hanley, M.D., Professor, Acute Care Neurology, Director, Division of Brain Injury Outcome Services, The Johns Hopkins Medical Institutions; Minesh Mehta, M.D., Director, Radiation Oncology and Deputy Director, Miami Cancer Institute, Baptist Health, Adjunct Professor, Radiation Oncology, University of Maryland College of Medicine; Michael Moskowitz, M.D., Professor of Neurology, Harvard College in Medicine, Neuroscientist, Dept. Neurology and Radiology, Massachusetts General Hospital; Graham Nichol, M.D., MPH, Professor of Medicine, University of Washington College of Medicine, Chair in Prehospital Emergency Care, Medical Director, Resuscitation Outcome Consortium Clinical Trial Center; Raymond Sawaya, M.D., Professor and Chairman, Dept. of Neurosurgery, University of Texas, MD Anderson Cancer Center, Adjunct Professor, Baylor College of Medicine; and J. Marc Simard, M.D., Ph.D, Professor of Neurosurgery, Pathology and Physiology, University of Maryland, College of Medicine and Scientific Founder of Remedy Pharmaceuticals. “After participating in Remedy Pharmaceuticals’ advisory board meeting, I believe CIRARA has a wide range of possible neuroinflammatory benefits that each deserve vigorous and detailed evaluation,” comments Daniel Hanley, M.D., Director, Division of Brain Injury Outcome Services, The Johns Hopkins Medical Institutions. “Edema is a major source of morbidity in a number of neurological disorders. [In brain cancer] most common therapy involves the use of corticosteroids that are known to cause significant side effects,” states Raymond Sawaya, M.D., Professor and Chairman of the Department of Neurosurgery at MD Anderson Cancer Center. “It is therefore with much anticipation, that Remedy’s drug, CIRARA, has shown great promise in reducing edema in both pre-clinical models as well as in clinical trials.” “This advisory board serves to complement and further inform our scientific direction and clinical objectives,” notes David Geliebter, Executive Chairman of Remedy Pharmaceuticals. “We are thrilled to have attracted such prominent physicians and scientists who share our interest in this transformative science.” ABOUT REMEDY PHARMACEUTICALS Remedy Pharmaceuticals, Inc. is a privately-held, clinical stage pharmaceutical company focused on developing and bringing lifesaving treatment to people affected by acute central nervous system (CNS) edema – including large hemispheric infarction, subarachnoid hemorrhage, and contusional traumatic brain injury, as well as other ischemic injuries and neurological disorders. Contact: Remedy Pharmaceuticals Sven Jacobson 212-586-2226 x 225 sven@remedypharmaceuticals.com PRESS RELEASE
Remedy Pharmaceuticals Issues Second Quarter 2016 Report NEW YORK, New York, July 6, 2016 — Remedy Pharmaceuticals, a privately-held pharmaceutical company focused on bringing life-saving hospital-based treatment to people affected by central nervous system related edema, today announced that the Company issued a second-quarter 2016 report. Highlights include newly analyzed data from 12-month follow-ups of patients in its Phase 2 randomized, double blind trial of CIRARA™ in large hemispheric infarctions. The report may be downloaded at http://www.remedypharmaceuticals.com/investor-information.html. ABOUT CIRARA CIRARA is a patented, high affinity inhibitor of Sur1-Trpm4 channels, which are upregulated following ischemia and trauma. Opening of these channels can lead to edema, midline shift, increased intracranial pressure and brain herniation, culminating in permanent disability or death. Sur1-Trpm4 channels were discovered by University of Maryland neurosurgeon Dr. J. Marc Simard, scientific founder and board member of Remedy Pharmaceuticals. CIRARA is suitable for intravenous delivery at the bedside or even in an ambulance. CIRARA uses our proprietary, patented MPD™ technology. CIRARA is an investigational drug and is not approved by FDA. ABOUT REMEDY PHARMACEUTICALS Remedy Pharmaceuticals, Inc. is a privately-held, clinical stage pharmaceutical company focused on developing and bringing lifesaving treatment to people affected by acute central nervous system edema – including large hemispheric infarction, subarachnoid hemorrhage, and contusional traumatic brain injury, as well as other ischemic injuries and neurological disorders. Contact: Remedy Pharmaceuticals Sven Jacobson 212-586-2226 x 225 sven@remedypharmaceuticals.com PRESS RELEASE
Roger Ulrich Joins Board of Remedy Pharmaceuticals Founder of Calistoga Pharmaceuticals, board member and former Chief Scientific Officer of Acerta Pharma to help guide future of company focused on ground-breaking therapy for CNS-related edema NEW YORK, New York, June 21, 2016 — Remedy Pharmaceuticals, a privately-held pharmaceutical company focused on bringing life-saving hospital-based treatment to people affected by central nervous system (CNS) related edema, today announced that Roger Ulrich has joined the company’s board of directors. In 2006 Dr. Ulrich co-founded Calistoga Pharmaceuticals, which was acquired by Gilead Sciences (NASDAQ:GILD) in 2011 in a transaction valued at up to $600 million. Dr. Ulrich left Gilead in 2012 to help build Acerta Pharma as a member of the Board and as acting Chief Scientific Officer. In February of this year, AstraZeneca (NYSE:AZN) acquired a 55% share of Acerta Pharma for $4 billion with an option to purchase the remainder of the company for $3 billion. Dr. Ulrich has many years of successful drug discovery and development experience. Prior to Acerta and Calistoga, Dr. Ulrich was senior scientific director with Merck Research Laboratories-Rosetta Inpharmatics (NYSE:MRK). Prior to Merck, Dr. Ulrich held various scientific and leadership positions within the pharmaceutical industry including Abbott Laboratories (now AbbVie, NYSE:ABBV), Pharmacia-Upjohn and The Upjohn Company, now part of Pfizer (NYSE:PFE). Prior to his pharmaceutical industry career, he worked at West Virginia and Michigan State Universities, and at Argonne National Laboratories. Dr. Ulrich has authored more than 125 publications and continues to serve on scientific and clinical advisory boards for industry, academia and government. Dr. Ulrich received his B.A. in biology/chemistry and his M.A. in biomedical sciences from Western Michigan University. He received a Ph.D. in cellular and molecular biology from West Virginia University, and is a fellow of the Academy of Toxicological Sciences. “We are honored to have Roger join our Board,” said David Geliebter, Executive Chairman of Remedy Pharmaceuticals. “He has achieved extraordinary success helping advance medicine, and is sure to be a tremendous asset as we move forward in achieving our mission of helping people afflicted with CNS-related edema to not only survive, but live life to the fullest.” “I am very excited to join the Board of Remedy, said Roger Ulrich. “The company’s underlying science is transformative and I look forward to working with the board and the team to help shape what I’m certain to be its bright future.” ABOUT CIRARA CIRARA is a patented, high affinity inhibitor of Sur1-Trpm4 channels, which are upregulated following ischemia and trauma. Opening of these channels can lead to edema, midline shift, increased intracranial pressure and brain herniation, culminating in permanent disability or death. Sur1-Trpm4 channels were discovered by University of Maryland neurosurgeon Dr. J. Marc Simard, scientific founder and board member of Remedy Pharmaceuticals. CIRARA is suitable for intravenous delivery at the bedside or even in an ambulance. CIRARA uses our proprietary, patented MPD™ technology. CIRARA is an investigational drug and is not approved by FDA. ABOUT REMEDY PHARMACEUTICALS Remedy Pharmaceuticals, Inc. is a privately-held, clinical stage pharmaceutical company focused on developing and bringing lifesaving treatment to people affected by acute central nervous system (CNS) edema – including large hemispheric infarction, subarachnoid hemorrhage, and contusional traumatic brain injury, as well as other ischemic injuries and neurological disorders. Contact: Remedy Pharmaceuticals Sven Jacobson 212-586-2226 x 225 sven@remedypharmaceuticals.com PRESS RELEASE
Remedy Pharmaceuticals Receives FDA Fast Track Designation for CIRARA™ NEW YORK, New York, June 8, 2016 — Remedy Pharmaceuticals, a privately-held pharmaceutical company focused on bringing life-saving hospital-based treatment to people affected by central nervous system (CNS) related edema, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its investigational drug, CIRARA, for the treatment of Large Hemispheric Infarctions (LHI). The Fast Track designation, established under the FDA Modernization Act of 1997, is designed to facilitate the development and expedite the review of drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. FDA may consider a "rolling review" of completed sections of the New Drug Application (NDA) before the complete application is submitted. Fast Track designation drugs ordinarily qualify for priority review, thereby expediting the FDA review process. “We are very pleased to achieve this additional important milestone for our LHI program, following the FDA’s recent acceptance of our investigational new drug (IND) application,” said Sven Jacobson, CEO of Remedy Pharmaceuticals. “This latest development provides further momentum as we advance CIRARA, with the near-term goal to initiate our phase 3 clinical trial by the end of this year.” ABOUT THE CHARM TRIAL AND LHI CHARM (Cirara in large Hemispheric infarction Analyzing modified Rankin & Mortality) is a phase 3 trial in patients with large hemispheric infarction (LHI). LHI is a devastating disease associated with significant disability and mortality. Brain swelling (often termed “malignant edema”) frequently occurs following LHI as a result of the opening of Sur1-Trpm4 channels in the capillary endothelium, which leads to dysfunction of the blood brain barrier. Such swelling can compromise arterial inflow to surrounding tissues, causing further ischemic damage and enlargement of the infarct, and frequently results in brain herniation and death. The risk of neurological deterioration and death is high, 40% to 80%. For a White Paper on LHI, please go to: http://www.remedypharmaceuticals.com/uploads/7/1/7/3/71731607/lhi.whitepaper.3jun16.pdf ABOUT CIRARA CIRARA is a patented, high affinity inhibitor of Sur1-Trpm4 channels, which are upregulated following ischemia and trauma. Opening of these channels can lead to edema, midline shift, increased intracranial pressure and brain herniation, culminating in permanent disability or death. Sur1-Trpm4 channels were discovered by University of Maryland neurosurgeon Dr. J. Marc Simard, scientific founder and board member of Remedy Pharmaceuticals. CIRARA is suitable for intravenous delivery at the bedside or even in an ambulance. CIRARA uses our proprietary, patented MPD™ technology. CIRARA is an investigational drug and is not approved by FDA. ABOUT REMEDY PHARMACEUTICALS Remedy Pharmaceuticals, Inc. is a privately-held, clinical stage pharmaceutical company focused on developing and bringing lifesaving treatment to people affected by acute central nervous system (CNS) edema – including large hemispheric infarction, subarachnoid hemorrhage, and contusional traumatic brain injury, as well as other ischemic injuries and neurological disorders. Contact: Remedy Pharmaceuticals Sven Jacobson 212-586-2226 x 225 sven@remedypharmaceuticals.com Remedy Pharmaceuticals Announces Contest to Name its Subarachnoid Hemorrhage Clinical Trial6/7/2016 PRESS RELEASE
Remedy Pharmaceuticals Announces Contest to Name its Subarachnoid Hemorrhage Clinical Trial NEW YORK, New York, June 7, 2016 — Remedy Pharmaceuticals, a privately-held pharmaceutical company focused on bringing life-saving hospital-based treatment to people affected by central nervous system (CNS) related edema, today announced a contest to name its upcoming clinical trial in Subarachnoid Hemorrhage (SAH). SAH is a serious, life-threatening condition. Each year some 30,000 to 35,000 people in the U.S. are afflicted by SAH, a type of stroke caused by bleeding into the space between the brain and the skull. Remedy Pharmaceuticals is planning to begin a Phase 2a clinical study of its drug CIRARA in patients with SAH. “We’re looking for an acronym that conveys the meaning of this trial,” notes, David Geliebter, Remedy’s Executive Chairman. “SAH is a serious subject, but it doesn’t mean we can’t have a little fun with our name contest.” Rules and entry instructions can be found at: www.remedypharmaceuticals.com/name-that-trial.html ABOUT CIRARA CIRARA is a patented, high affinity inhibitor of Sur1-Trpm4 channels, which are upregulated following ischemia and trauma. Opening of these channels can lead to edema, midline shift, increased intracranial pressure and brain herniation, culminating in permanent disability or death. Sur1-Trpm4 channels were discovered by University of Maryland neurosurgeon Dr. J. Marc Simard, scientific founder and board member of Remedy Pharmaceuticals. CIRARA is suitable for intravenous delivery at the bedside or even in an ambulance. CIRARA uses our proprietary, patented MPD™ technology. CIRARA is an investigational drug and is not approved by FDA. ABOUT REMEDY PHARMACEUTICALS Remedy Pharmaceuticals, Inc. is a privately-held, clinical stage pharmaceutical company focused on developing and bringing lifesaving treatment to people affected by acute central nervous system (CNS) edema – including large hemispheric infarction, subarachnoid hemorrhage, and contusional traumatic brain injury, as well as other ischemic injuries and neurological disorders. Contact: Remedy Pharmaceuticals Sven Jacobson 212-586-2226 x 225 sven@remedypharmaceuticals.com PRESS RELEASE
Remedy Pharmaceuticals’ New Website Spotlights Victims of CNS-Related Edema NEW YORK, New York, May 5, 2016 — Remedy Pharmaceuticals, a privately-held pharmaceutical company focused on bringing life-saving hospital-based treatment to people affected by central nervous system (CNS) related edema, today announced that the Company has launched a new website, CiraraStories.com, which will feature people afflicted by this devastating condition – patients, their families, and the medical professionals who care for them. The video stories are sponsored by Remedy Pharmaceuticals, makers of CIRARA™, a drug designed to prevent edema formation. The inaugural video profiles a remarkable woman, Jaclyn who, at age 32, had a large hemispheric infarction (LHI). The LHI occurred the night before her middle child was to start school for the first time. She had just set out his lunch box, went upstairs, and as she lay down on the bed, a strange sensation came over her. Jaclyn tried getting out of bed, but fell, hitting her head on the nightstand, which woke her husband, Jim. Startled, he jumped out of bed and saw his wife lying on the floor, her head bloodied. Jaclyn was paralyzed on her right side and unable to speak. She could only blink her eyes. Jim called 911. We learn what happened when Jaclyn’s family discovered her chances of surviving were poor, the difficult decision they had to make, and how she is doing now. “Jaclyn’s story reminds us of the important mission we are on to help CNS-related edema victims to not only survive, but live life to the fullest,” notes David Geliebter, Executive Chairman of Remedy Pharmaceuticals. ABOUT CIRARA CIRARA is a patented, high affinity inhibitor of Sur1-Trpm4 channels, which are upregulated following ischemia and trauma. Opening of these channels can lead to edema, midline shift, increased intracranial pressure and brain herniation, culminating in permanent disability or death. Sur1-Trpm4 channels were discovered by University of Maryland neurosurgeon Dr. J. Marc Simard, scientific founder and board member of Remedy Pharmaceuticals. CIRARA is suitable for intravenous delivery at the bedside or even in an ambulance. CIRARA uses our proprietary, patented MPD™ technology. CIRARA is an investigational drug and is not approved by FDA. ABOUT REMEDY PHARMACEUTICALS Remedy Pharmaceuticals, Inc. is a privately-held, clinical stage pharmaceutical company focused on developing and bringing lifesaving treatment to people affected by acute central nervous system (CNS) edema – including large hemispheric infarction and contusional traumatic brain injury, as well as other ischemic injuries and neurological disorders. ABOUT CIRARASTORIES.COM CiraraStories may be accessed at www.cirarastories.com. CIRARA is an investigational drug and is not approved for use. The safety and efficacy of CIRARA has not been established and is currently under investigation. CIRARA stories are presented to create awareness about CNS-related edema. Contact: Remedy Pharmaceuticals Sven Jacobson 212-586-2226 x 225 sven@remedypharmaceuticals.com |
RSS Feed
|
Copyright © 2021. Remedy Pharmaceuticals, Inc. / Embark Healthcare - All rights reserved.
|
Website by CG Media LLC
|